Dr. Yucai Wang is the Founder and Chief Scientist of AlphaNa Bioscience and a Professor at the University of Science and Technology of China (USTC). He received his bachelor’s and Ph.D. degrees from USTC and completed postdoctoral training at Washington University in St. Louis, the Georgia Institute of Technology, and the University of Chicago.
Dr. Wang’s research and translational work focus on RNA therapeutics, nucleic acid delivery technologies, and immune cell engineering. He has led the development and industrial translation of multiple next-generation nucleic acid drugs and vaccines, resulting in six investigational new drug approvals from the National Medical Products Administration (NMPA), including programs currently in Phase I and Phase II clinical trials. His work also includes the advancement of in vivo CAR-T and tolerogenic antigen-presenting cell (Tol-APC) platforms through preclinical and investigator-initiated studies.
Dr. Wang has published more than 100 peer-reviewed articles in leading journals, including Science and Nature Nanotechnology, with over 9,000 citations. As Founder and Chief Scientist, he leads a multidisciplinary R&D team dedicated to translating fundamental discoveries into clinically meaningful therapeutics.

Dr. Chao Wang is a Co-Founder of AlphaNa Bioscience and a Professor at the University of Science and Technology of China (USTC). He received his bachelor’s degree from Shanghai Jiao Tong University and his Ph.D. from The Hong Kong University of Science and Technology (HKUST).
Dr. Wang’s research and translational work focus on structural biology, antigen design, and the molecular mechanisms underlying cellular function. As a key scientific and translational leader, he has contributed to the development and clinical advancement of innovative vaccine programs, supporting six investigational new drug approvals from the National Medical Products Administration (NMPA), including candidates in Phase I and Phase II clinical trials.
Dr. Wang has published extensively as a corresponding author in leading journals, including Nature Chemical Biology, Nature Metabolism, and PNAS. He is a recipient of the NSFC Excellent Young Scientist Fund and the Chinese Academy of Sciences Pioneer Hundred Talents Program. At AlphaNa Bioscience, he leads multidisciplinary research teams, translating structural and mechanistic insights into clinically relevant therapeutic strategies.